NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00703-5075-03 | 00703-5075 | Dacarbazine | Dacarbazine | 200.0 mg/20mL | Chemotherapy | Alkylating Agent | Purine Analog | Intravenous | Aug. 27, 1998 | Feb. 29, 2024 | No Longer Used |
14789-0013-10 | 14789-0013 | Busulfan | Busulfan | 60.0 mg/10mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Sept. 15, 2023 | July 21, 2024 | No Longer Used |
16729-0545-63 | 16729-0545 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Aug. 18, 2022 | In Use | |||
16729-0548-63 | 16729-0548 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Aug. 18, 2022 | In Use | |||
43598-0660-11 | 43598-0660 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | July 24, 2023 | In Use | |
51991-0890-33 | 51991-0890 | Erlotinib Hydrochloride | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 5, 2019 | April 30, 2024 | No Longer Used |
58468-7860-03 | 58468-7860 | Vandetanib | CAPRELSA | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | June 24, 2022 | In Use | |
63459-0177-14 | 63459-0177 | Omacetaxine Mepesuccinate | Synribo | 3.5 mg/mL | Chemotherapy | Plant Alkaloid | BCR-ABL | Subcutaneous | Nov. 19, 2012 | April 30, 2024 | No Longer Used |
70860-0203-50 | 70860-0203 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | April 30, 2024 | No Longer Used |
72266-0125-01 | 72266-0125 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb. 15, 2019 | In Use | |
72266-0125-10 | 72266-0125 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | April 2, 2019 | In Use | |
72266-0126-01 | 72266-0126 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb. 15, 2019 | In Use | |
72266-0126-10 | 72266-0126 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | April 2, 2019 | In Use | |
25021-0259-50 | 25021-0259 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 1, 2024 | In Use | |
25021-0259-51 | 25021-0259 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 1, 2024 | In Use | |
46708-0813-50 | 46708-0813 | Nelarabine | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 1, 2024 | In Use | |
46708-0813-63 | 46708-0813 | Nelarabine | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 1, 2024 | In Use | |
62332-0813-50 | 62332-0813 | Nelarabine | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 1, 2024 | In Use | |
62332-0813-63 | 62332-0813 | Nelarabine | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 1, 2024 | In Use | |
51407-0909-01 | 51407-0909 | HYDROXYUREA | HYDROXYUREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | April 22, 2024 | In Use | |
55150-0395-08 | 55150-0395 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | June 25, 2024 | In Use | |
55150-0496-10 | 55150-0496 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | April 8, 2022 | In Use | |
55150-0497-10 | 55150-0497 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | April 8, 2022 | In Use | |
55150-0498-01 | 55150-0498 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | April 8, 2022 | In Use | |
55150-0499-01 | 55150-0499 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | April 8, 2022 | In Use |
Found 10,000 results in 9 milliseconds — Export these results